Evan Melrose
Austin, United States
Evan Melrose is a Series B investor at Elevage Medical Technologies in Austin focused on Medical and Health Care. Evan Melrose is based out of Austin, Texas, and is the CEO of Elevage Medical Technologies and also Board of Directors of Imperative Care. Evan previously worked at Medtronic as a Board of Directors. Evan Melrose attended the University of Pennsylvania. Evan Melrose has been awarded as a Kentucky Colonel.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Evan Melrose invests in
Stages Evan Melrose invests in
Countries Evan Melrose invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (33%)
- Health Care 2 (33%)
- Medical Device 2 (33%)
- Hospital 1 (17%)
- Analytics 1 (17%)
Stage
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Series E 1 (17%)
- Debt Financing 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Imperative Care
|
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M / Convertible Note / Mar 17, 2026 | |
Biobeat
|
Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $50M / Series B / Dec 30, 2025 | |
Elucid
|
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $80M / Series C / Nov 09, 2023 | |
HNI Healthcare
|
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metricsthrough a more clinically integrated care model. | $33.3M / Series E / Jan 23, 2018 | |
Qspex Technologies
|
QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer tobecome part of the lens during the polymerization (curing) process. | $34.5M / Debt Financing / Jul 17, 2015 | |
|
Qspex Technologies
|
QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer tobecome part of the lens during the polymerization (curing) process. | $20.5M / Series D / Jun 07, 2012 |
Co-Investors
Ally Bridge Group
2 deals together
Essex Woodlands Healthcare Partners
2 deals together
Bain Capital Life Sciences
1 deal together
Bison Capital Asset Management
1 deal together
Brown Advisory
1 deal together
Catalio Capital Management
1 deal together
Elevage Medical Technologies is dedicated to supporting medical device companies that can meaningfully improve health outcomes and quality of life for patients.
Elevage Medical Technologies Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Evan Melrose
CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Evan Melrose invest in?
Evan Melrose invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Evan Melrose?
Public channels for Evan Melrose include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Evan Melrose last invest?
The most recent investment recorded for Evan Melrose closed in Mar 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
